Ethiopian Food and Drug Authority (EFDA)

GUIDANCE ON WAIVER OF IN VIVO BIOEQUIVALENCE REQUIREMENTS

Second Edition

July, 2021
Addis Ababa, Ethiopia
Contents

ABBREVIATION ........................................................................................................................................ iii

1. INTRODUCTION .................................................................................................................................. 1

2. DEFINITION ......................................................................................................................................... 3

3. SCOPE .................................................................................................................................................. 3

4. BIOWAIVER BASED ON BIOPHARMACEUTICAL CLASSIFICATION SYSTEM (BCS) .................... 5

   4.1. Biopharmaceutics classification system (BCS) ............................................................................. 5

      4.1.1. Solubility .................................................................................................................................... 6

      4.1.2. Permeability ............................................................................................................................. 6

      4.1.3. Dissolution ............................................................................................................................... 6

   4.2. Other parameters to be considered for BCS based biowaiver ...................................................... 7

      4.1.1. Excipients used in the formulation ......................................................................................... 7

      4.1.2. Risk Assessment ....................................................................................................................... 7

   4.3. Selection of comparator (reference) product ................................................................................... 8

   4.4. Criteria for acceptance of BCS based biowaiver for a pharmaceutical product ......................... 8

   4.5. Regulatory applications of the BCS on post approval change ..................................................... 10

5. BIOWAIVERS BASED ON DOSE-PROPORTIONALITY OF FORMULATIONS ................................. 11

   5.1. Proportionally similar formulations ................................................................................................. 11

   5.2. Qualification for biowaiver based on dose-proportionality of formulations ............................... 12

      5.2.1. Immediate-release tablets ......................................................................................................... 12

      5.2.2. Delayed-release tablets and capsules ....................................................................................... 13

      5.2.3. Extended-release beaded capsules ............................................................................................ 14

      5.2.4. Extended-release tablets ......................................................................................................... 14

   5.3. Dissolution profile comparison for biowaivers based on dose-proportionality of formulations .......... 14

6. DATA TO SUPPORT A REQUEST FOR BIOWAIVERS ....................................................................... 16

REFERENCE ............................................................................................................................................. 44
## ABBREVIATION

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>API</td>
<td>Active Pharmaceutical Product</td>
</tr>
<tr>
<td>BA</td>
<td>Bioavailability</td>
</tr>
<tr>
<td>BCS</td>
<td>Biopharmaceutics Classification System</td>
</tr>
<tr>
<td>BMR</td>
<td>Batch manufacturing Record</td>
</tr>
<tr>
<td>CoA</td>
<td>Certificate of Analysis</td>
</tr>
<tr>
<td>EFDA</td>
<td>Ethiopian Food and Drug Authority</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicine Agency</td>
</tr>
<tr>
<td>FDC</td>
<td>Fixed Dose Combinations</td>
</tr>
<tr>
<td>FPP</td>
<td>Finished Pharmaceutical Product</td>
</tr>
<tr>
<td>IR</td>
<td>Immediate Release</td>
</tr>
<tr>
<td>NMT</td>
<td>Not More Than</td>
</tr>
<tr>
<td>QC</td>
<td>Quality Control</td>
</tr>
<tr>
<td>U.S. FDA</td>
<td>United States Food and Drug Administration</td>
</tr>
<tr>
<td>USP</td>
<td>United States Pharmacopeia</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

The term biowaiver is applied to a regulatory drug approval process where the efficacy and safety part of the dossier (application) is approved based on evidence of in vitro equivalence other than through in vivo equivalence testing i.e. use of in vitro testing as a reliable surrogate for an in vivo BE study. A major advantage of the biowaiver procedure is the simplification of the product approval process and the reduction of the time required, thus reducing the cost of bringing new products to market.

This guidance on bioavailability/bioequivalence lays down the requirements for waiver of in vivo bioavailability/bioequivalence requirements for immediate release solid oral dosage forms, dose-proportionality formulation and significant post approval changes.

Biowaiver can be applied only for products which meet requirements on pharmaceutical equivalent, as well as similarity in comparative dissolution tests.

The BCS class of APIs indicated in different regulatory guidelines, scientific articles and public assessment reports such as WHO guidelines, US FDA, EMA etc. in such case, therefore, not necessary to provide data to support the BCS classification of the respective API(s) in the application i.e. data supporting the drug substance solubility or permeability class.

There are different areas in which biowaiver is applicable for. These include:

1. Formulation development for new drug product. During development, formulation changes are inevitable resulting in differences between clinical batches used in Phase II (proof of principle), phase III (pivotal formulations) and ultimate commercial batches. Equivalence between initial batches (clinical) and commercial batches must be established.

2. Line extensions: These include new strengths, new dosage formulations for specific groups e.g. paediatric population. Applications for biowaivers of additional strengths of a submitted (test) product, based on proportionality of formulations and comparative in vitro dissolution data, must include data on comparative dissolution between the different
strengths of the test product and also against the respective strengths of the comparator product.

3. Formulation development of a generic drug product. A generic product must be comparable to the innovator product i.e. must be therapeutically equivalent and interchangeable. This means the generic product must be pharmaceutically equivalent and bioequivalent to meet therapeutic equivalence.

4. Post approval changes: considered as major variation in formulation, excipients and or manufacturing process. The changes are classified according to the potential impact on the formulation quality and performance.
2. DEFINITION

Biowaiver

The term biowaiver is applied to a regulatory drug approval process when the dossier (application) is approved based on evidence of equivalence other than through in vivo equivalence testing.

Comparator product

The comparator product is a pharmaceutical product with which the multisource product is intended to be interchangeable in clinical practice.

Fixed-dose combination (FDC)

A combination of two or more active pharmaceutical ingredients in a fixed ratio of doses. This term is used generically to mean a particular combination of active pharmaceutical ingredients irrespective of the formulation or brand. It may be administered as single-entity products given concurrently or as a finished pharmaceutical product.

Pharmaceutical equivalence

Products are pharmaceutical equivalents if they contain the same molar amount of the same active pharmaceutical ingredient(s) in the same dosage form, if they meet comparable standards, and if they are intended to be administered by the same route. Pharmaceutical equivalence does not necessarily imply therapeutic equivalence, as differences in the excipients and/or the manufacturing process and some other variables can lead to differences in product performance.

3. SCOPE

This document is intended to provide guidance on EFDA biowaiver implementation.

The requirements set in this guidance document are applicable to new applications for registration of a pharmaceutical product based BCS classifications, dose proportionate
formulation (usually for lower strengths) and variation to registered products which have systemic action of oral solid dosage form.

Multisource products as described in section 1 of Annex IV: requirement for bioequivalence study of Guideline for Registration of Medicines (EFDA), 2020 their availability are self-evidence and not require bioequivalence study are not covered in guidance document.

Locally acting medicines such as locally acting antacids and anti-helminthic do not require Bioequivalence study are not covered in this guidance document.
4. BIORAVER BASED ON BIOPHARMACEUTICAL CLASSIFICATION SYSTEM (BCS)

4.1. Biopharmaceutics classification system (BCS)

Biopharmaceutics Classification system (BCS) is a scientific framework for classifying APIs into four groups based on their aqueous solubility and intestinal permeability properties. According to the BCS, drug substances are classified as follows:

- **Class I**: high solubility – high permeability
- **Class II**: low solubility – high permeability
- **Class III**: high solubility – low permeability
- **Class IV**: low solubility – low permeability

When combined with the dissolution of the Finished Pharmaceutical Product, the BCS takes into account three major factors that govern the rate and the extent drug absorption from immediate Release (IR) solid oral dosage forms: in vitro dissolution, solubility and intestinal permeability.

Observed in vivo differences in the rate and extent of absorption of a drug from two pharmaceutically equivalent solid oral products may be due to differences in drug dissolution in vivo. However, when the in vivo dissolution of an IR solid oral dosage form is rapid or very rapid in relation to gastric emptying and the drug has high solubility, the rate and extent of drug absorption is unlikely to be dependent on drug dissolution and/or gastrointestinal (GI) transit time. Under such circumstances, demonstration of in vivo BA or BE may not be necessary for drug products containing class I and class III drug substances, as long as the inactive ingredients used in the dosage form do not significantly affect absorption of the active ingredients.

On the basis of solubility and permeability of the API, excipient nature, excipient content and dissolution characteristics of the dosage form, the BCS approach provides an...
opportunity to waive in vivo bioequivalence testing for certain categories of immediate-release FPPs. Oral FPPs containing an API possessing a narrow therapeutic index are not eligible for a so-called biowaiver based on the BCS approach.

The recommended methods for determining solubility, permeability and in vitro dissolution are discussed below.

4.1.1. Solubility
The solubility class boundary is based on the highest dose strength of an IR product that is subject of a biowaiver request. A drug substance is considered **highly soluble**, when the highest oral dose or the highest single dose / strength to be marketed is soluble in 250 ml or less of aqueous media at 37±1°C over a pH range of 1.2–6.8. A minimum of three replicate determinations of solubility at each pH condition is recommended.

4.1.2. Permeability
The permeability class boundary is based indirectly on the extent of absorption (fraction of dose absorbed, not systemic BA) of a API in humans and directly on measurements of the rate of mass transfer across human intestinal membrane. Alternatively, other systems capable of predicting the extent of drug absorption in humans can be used (e.g., in situ animal, in vitro epithelial cell culture methods). An API is considered **highly permeable**, when the extent of absorption in humans is 85% or more based on a mass balance determination or in comparison with an intravenous comparator dose.

4.1.3. Dissolution
In this guidance, a multisource product is considered to be

- **Rapidly dissolving** when no less than 85% of the labelled amount of the drug substance dissolves in 30 minutes using a paddle apparatus at 75 rpm or a basket apparatus at 100 rpm in a volume of 900 ml or less in each of the following media: pH 1.2 HCl solution or Simulated Gastric Fluid USP without enzymes; a pH 4.5 acetate buffer; and a pH 6.8 phosphate buffer or Simulated Intestinal Fluid USP without enzymes.
• **Very rapidly dissolving** when no less than 85% of the labeled amount of the drug substance dissolves in 15 minutes using a paddle apparatus at 75 rpm or a basket apparatus at 100 rpm in a volume of 900 ml or less in each of the following media: a pH 1.2 HCl solution or Simulated Gastric Fluid USP without enzymes; a pH 4.5 acetate buffer; and a pH 6.8 phosphate buffer or Simulated Intestinal Fluid USP without enzymes.

4.2. Other parameters to be considered for BCS based biowaiver

4.1.1. **Excipients used in the formulation**
Excipients can sometimes influence motility and/or permeability in the gastrointestinal tract thereby affects the rate and extent of drug absorption. Therefore, the excipients used in the multisource product formulation should be scrutinized.

When new excipients or atypically large amounts of commonly used excipients are included in an IR solid dosage form, additional information documenting the absence of an impact on BA of the drug may be requested by the Authority. Large quantities of certain excipients, such as surfactants (e.g., polysorbate 80) and sweeteners (e.g., mannitol or sorbitol) may be problematic.

If the multisource product under consideration contains excipients that have been used before in similar amounts in other formulations of the same API, it can be reasonably concluded that these excipients will have no unexpected consequences for the bioavailability of the product.

If, however, the formulation contains different excipients, or amounts of the same excipients that are very different from usual, the Authority may choose to declare the biowaiver procedure inapplicable.

4.1.2. **Risk Assessment**
To minimize the risks of an incorrect biowaiver decision in terms of public health and risks to individual patients, the therapeutic indications of the API, known pharmacokinetic variations, food effects, etc. should be evaluated based on local clinical experience, taking into account the indications for which the API is prescribed in that country as well as specific pharmacokinetic population variations (for example CYP polymorphisms). Hence, as an
addition to the excipients used in the formulation, the below conditions can serve as exclusion criteria from biowaiver.

- A product that contain an API with a narrow therapeutic index;
- A product designed to be absorbed from other sites e.g. from the oral cavity;
- A fixed-dose combination product that contain an API where biowaiver is not applicable; and

Only when there is an acceptable benefit–risk balance in terms of public health and risk to the individual patient should bioequivalence testing according to the guidance given in this section be permitted.

4.3. Selection of comparator(reference) product

Identification of comparator product is essential in the biowaiver application. The choice of comparator product should be justified by the applicant. The country of origin of the comparator product should be reported together with lot number and expiry date. The country of origin of the comparator product should be from a well-regulated market and should be traceable, whenever required.

The comparator product will normally be the innovator product for which efficacy, safety and quality have been established. The choice of the comparator product should be as per section 4.8 of annex IV: Requirements for Bioequivalence study of Guideline for registration of medicines. Furthermore, applicant can follow guidance on selection of comparator pharmaceutical products for equivalence assessment of interchangeable multisource (generic) products, annex 8, WHO TRS 992 in the selection of comparator product for biowaiver application.

4.4. Criteria for acceptance of BCS based biowaiver for a pharmaceutical product

a. Dosage forms of APIs which are highly soluble, highly permeable (BCS Class I) with acceptable excipient content and favorable risk-benefit analysis and which are rapidly dissolving are eligible for a biowaiver based on the BCS provided:
• The dosage form is *rapidly dissolving* (as defined in section 3.3 of this guidance document) and the dissolution profile of the multisource product is similar to that of the comparator product in aqueous buffers at pH 1.2 or Simulated Gastric Fluid USP without enzymes, pH 4.5 and pH 6.8 or Simulated Intestinal Fluid USP without enzymes using the paddle method at 75 rpm or the basket method at 100 rpm and meets the criteria of dissolution profile similarity, $f_2 \geq 50$ (or equivalent statistical criterion);

• If both the comparator and the multisource dosage forms are *very rapidly dissolving* (85% in 15 minutes) the two products are deemed equivalent and a profile comparison is not necessary.

b. Dosage form of APIs that are highly soluble and have low permeability (BCS Class III) are eligible for biowaiver provided that the following three and the risk-benefit is additionally addressed in terms of extent, site and mechanism of absorption

• Both the comparator and the multisource dosage forms are very rapidly dissolving (release of > 85% of the labelled amount of drug in 15 minutes) in standard media at pH 1.2 or Simulated Gastric Fluid USP without enzymes, 4.5 and 6.8 or Simulated Intestinal Fluid USP without enzymes, at a rotational speed of 75 rpm in the paddle apparatus or 100 rpm in the basket apparatus.

• All the excipients in the proposed product formulation should be qualitatively the same and quantitatively similar to that of the comparator product, as defined by WHO quality limits on allowable quantitative changes in excipients for a variations Annex I of this document.

• The risks of incorrect biowaiver decision in terms of the therapeutic index of and clinical indication for APIs is absent.

c. Fixed dose combination (FDC) product with class I and or III APIs meeting the dissolution criteria as specified above.
d. Evidence to show that the excipients included are the same (i.e. same ratios and amounts) as the comparator product or that the excipients used do not influence the absorption of the API

**Note on Dissolution profile comparison:** Approval of multisource formulations using comparative in vitro dissolution studies should be based on the generation of comparative dissolution profiles rather than a single-point dissolution test. For details refer to Annex IV.

**4.5. Regulatory applications of the BCS on post approval change**

BCS-based biowaivers can be requested for significant changes such as change in composition, excipients and manufacturing process to a rapidly dissolving IR product containing highly soluble, highly permeable drug substance, provided that dissolution remains rapid for the post-change product and both pre- and post-change products exhibit similar dissolution profiles. This approach is useful only when the drug products pre- and Post-change are pharmaceutical equivalent.
5. BIOWAIVERS BASED ON DOSE-PROPORTIONALITY OF FORMULATIONS

Under certain conditions, approval of different strengths of a multisource product can be considered on the basis of dissolution profiles if the formulations have proportionally similar compositions.

5.1. Proportionally similar formulations

For the purpose of this guidance proportionally similar formulations can be defined in two ways, based on the strength of dosage forms.

a. All active and inactive ingredients are exactly in the same proportions in the different strengths (e.g. a tablet of 50 mg strength has all the active and inactive ingredients exactly half that of a tablet of 100 mg strength, and twice that of a tablet of 25 mg strength). For immediate release products, coating components, capsule shell, colour agents and flavours are not generally required to meet this requirement.

b. For a high potency API, where the amount of the API in the dosage form is relatively low (up to 10 mg per dosage unit or NMT 5% of the weight of the dosage form), the total weight of the dosage form remains similar for all strengths.

For (b) a waiver is considered:

- If the amounts of the different excipients or capsule contents are the same for the strengths considered and only the amount of the API has changed;
- If the amount of filler is changed to account for the change in the amount of API: the amounts of the other core excipients or capsule content should be the same for the strengths concerned.
5.2. Qualification for biowaiver based on dose-proportionality of formulations

Dose-proportionality of formulations can be eligible for a biowaiver if

a. the multisource product at one strength (usually higher strength, ) has been shown in in-vivo studies to be bioequivalent to the corresponding strength of the comparator product;

b. the other strengths of the multisource product are proportionally similar in formulation to that of the higher strength for which bioequivalence with the comparator has been confirmed as per section 5.1 above.

c. When both of these criteria (i.e. criteria under a & b above) are met and the dissolution profiles of the other strengths are shown to be similar to that of the higher strength, for which bioequivalence with the comparator has been confirmed, on a percentage released against time basis, the biowaiver procedure can be considered for the lower strengths.

As in the case of biowaivers based on the BCS, a biowaiver based on dose proportionality of formulations should be considered only when there is an acceptable benefit–risk balance in terms of public health and risk to the individual patient.

5.2.1. Immediate-release tablets

A biowaiver based on the dose proportionality of formulations for a series strengths of a multisource product, when the pharmaceutical products are manufactured with the same manufacturing process may be granted when:

a. An in vivo equivalence study has been performed on at least one of the strengths of the formulation. As described in above, the strength studied will usually be the highest strength, unless a lower strength is chosen for reasons of safety or the API is highly soluble and displays linear pharmacokinetics)

b. All strengths are proportionally similar in formulation to that of the strength studied (see section 5.1 above);

c. The dissolution profiles for the different strengths are similar at pH 1.2, 4.5, 6.8 and for the QC media, unless justified by the absence of sink conditions. If the different strengths of the test product do not show similar dissolution profiles owing to the
absence of sink conditions in any of the above media, this should be substantiated by showing similar dissolution profiles when testing the same dose per vessel (e.g. two tablets of 5 mg versus one tablet of 10 mg) or by showing the same behavior in the comparator product.

As for the biowaiver based on BCS, if both strengths release 85% or more of the label amount of the API in 15 minutes, using all three dissolution media as recommended Annex IV of this guidance, the profile comparison with an f2 test is unnecessary.

In the case where an immediate-release dosage form with several strengths deviates from proportionality a bracketing approach is possible, so that only two strengths representing the extremes need to be studied in vivo.

If approval of one strength of a product is based on a BCS-based biowaiver instead of an in vivo equivalence study, other strengths in the series of strengths should also be assessed based on BCS-based biowaivers as opposed to a biowaiver based on dose proportionality.

### 5.2.2. Delayed-release tablets and capsules

For delayed-release tablets, when the multisource product is in the same dosage form, but in a different strength, and is proportionally similar in its active and inactive ingredients and has the same delayed-release mechanism, a lower strength can be granted a biowaiver if it exhibits similar dissolution profile, f2 > 50, in the recommended test condition for delayed-release product, i.e. dissolution test in acid medium (pH 1.2) for 2 hours followed by dissolution in pH 6.8. When evaluating proportionality in composition, it is recommended to consider the proportionality of gastro-resistant coating with respect to the surface area (not to core weight) to have the same gastro-resistance (mg/cm2).

For delayed-release capsules, where different strengths have been achieved solely by means of adjusting the number of beads containing the API, similarity in the dissolution profile of the lower strength to that of the approved strength (f2 > 50) under the test conditions recommended for delayed-release products (see above paragraph) is sufficient for a biowaiver.
5.2.3. **Extended-release beaded capsules**

For extended-release beaded capsules, where different strengths have been achieved solely by means of adjusting the number of beads containing the API, dissolution profile comparison ($f_2 \geq 50$) under one recommended test condition (normally the release condition) is sufficient for a biowaiver based on dose-proportionality of formulation.

5.2.4. **Extended-release tablets**

For extended-release tablets, when there is a series of strengths of a multisource product that are proportionally similar in their active and inactive ingredients and have the same API-release mechanism, in vivo bioequivalence studies should be conducted with the highest proposed strength. Subsequently, lower strengths in the series can be granted a biowaiver if they exhibit similar dissolution profiles to the highest strength, $f_2 \geq 50$, in three different pH buffers (between pH 1.2 and 7.5) and the QC media by the recommended test method.

For extended-release tablets with an osmotic pump release mechanism, the dissolution profile comparison ($f_2 \geq 50$) under one recommended test condition is sufficient for a biowaiver based on dose-proportionality of formulation.

5.3. **Dissolution profile comparison for biowaivers based on dose-proportionality of formulations**

As for biowaivers based on the BCS, a model independent mathematical approach (e.g. $f$ test) can be used for comparing the dissolution profiles of two products. The dissolution profile of the two products (reference strength and additional strength) should be measured under the same test conditions.

The dissolution sampling times for both multisource and comparator product profiles should be the same:

— for immediate-release products 5, 10, 15, 20, 30, 45 and 60 minutes;
— for 12-hour extended-release products 1, 2, 4, 6 and 8 hours; and
— for 24-hour extended-release products 1, 2, 4, 6, 8 and 16 hours.
Only one time-point should be considered after 85% dissolution from the comparator product. An f-value of 50 or greater (50–100) reflects equivalence (less than 10% difference) of the two curves, and thus equivalence of in vitro performance of the two products. To allow the use of the mean data, the coefficient of variation should not be more than 20% at the earliest time-point (e.g. 10 minutes in the case of the example given for immediate-release products), and should not be more than 10% at other time points.
6. DATA TO SUPPORT A REQUEST FOR BIOWAIVERS

- Filled application form as per the annexes i.e. Annex II for biowaver request based on BCS and Annex III for biowaver based on dose-proportionality formulation.
- For BCS based biowaver request, data supporting solubility and permeability of the APIs should be reported and thereby, the BCS class of API should be specified based on the scientific data.
- For submission biowaver request, data supporting dissolution attributes of the test and reference (comparator) products should be reported.
- Dissolution data obtained with 12 individual units of the test and reference (comparator) products using recommended test methods as outline in annex IV of this guidance. The percentage of labeled claim dissolved at each specified testing interval should be reported for each individual dosage unit. The mean percentage dissolved, range (highest and lowest) of dissolution, and coefficient of variation (relative standard deviation) should be tabulated. A graphic representation of the mean dissolution profiles for the test and reference (comparator) products in the three media should also be included.
- Data supporting similarity in dissolution profiles between the test and reference (comparator) products in each of the three media, using the \( f_2 \) matrices.
- The manufacturing process used to make the test product should be described briefly to provide information on the method of manufacture. A list of excipients used with their amount and intended functions should be provided.
Annex I: Limits on the relative difference in the amount of excipient in two solid oral FPPs to be considered quantitatively similar in that excipient

<table>
<thead>
<tr>
<th>Excipient type</th>
<th>Percentage difference (w/w) out of total product (core) weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filler</td>
<td>5.0</td>
</tr>
<tr>
<td>Disintegrant</td>
<td></td>
</tr>
<tr>
<td>Starch</td>
<td>3.0</td>
</tr>
<tr>
<td>Other</td>
<td>1.0</td>
</tr>
<tr>
<td>Binder</td>
<td>0.5</td>
</tr>
<tr>
<td>Lubricant</td>
<td></td>
</tr>
<tr>
<td>Calcium or magnesium stearate</td>
<td>0.25</td>
</tr>
<tr>
<td>Other</td>
<td>1.0</td>
</tr>
<tr>
<td>Glidant</td>
<td></td>
</tr>
<tr>
<td>Talc</td>
<td>1.0</td>
</tr>
<tr>
<td>Other</td>
<td>0.1</td>
</tr>
</tbody>
</table>

If an excipient serves multiple functions (e.g. microcrystalline cellulose as a filler and as a disintegrant) then the most conservative recommended range should be applied (e.g. ± 1.0% for microcrystalline cellulose should be applied in this example). The relative concentration of an excipient present in two aqueous solution FPPs is considered to be similar if the difference is $\leq 10\%$. 
Annex II: Biowaiver Application Form: Biopharmaceutics Classification System (BCS)

This application form is designed to facilitate information exchange between the Applicant and the EFDA on Medicines if the Applicant seeks to waive bioequivalence studies based on the Biopharmaceutics Classification System (BCS).

For those of APIs that have known evidence on BCS classes in guidelines of regulators (such as WHO, USFDA, EMA etc), Public assessment reports and scientific articles, it may not necessary to provide data to support the BCS classification of the respective API(s) in the application i.e. data supporting the drug substance solubility or permeability class.

**Administrative data**

<table>
<thead>
<tr>
<th>1. Name of the product (brand and INN active ingredient(s))</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;&lt; Please enter information here &gt;&gt;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. Dosage form and strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;&lt; Please enter information here &gt;&gt;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. Name of applicant and official address</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;&lt; Please enter information here &gt;&gt;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. Name of manufacturer of finished product and official address</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;&lt; Please enter information here &gt;&gt;</td>
</tr>
</tbody>
</table>
4. Name of Local agents and local address

<< Please enter information here >>

6. Name and address of the laboratory or Contract Research Organisation(s) where the BCS-based biowaiver solubility and dissolution studies were conducted

<< Please enter information here >>

I, the undersigned, certify, that the information provided in this application and the attached documents is correct and true

Signed on behalf of
<company>

_________________________ (Date)

________________________________ (Name and title)
1. Justification for a BCS Biowaiver

<table>
<thead>
<tr>
<th>1.1. Active Pharmaceutical Ingredient (API)</th>
<th>Please confirm that the proposed product contains the same active substance (e.g. salt, ester, ether, isomer) as the comparator.</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;&lt; Please enter information here &gt;&gt;</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1.2. Therapeutic Index of the API</th>
<th>Please enclose a copy of the comparator product labelling and literature references employed to support that the drug does not exhibit a narrow therapeutic index for all authorised indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;&lt; Please enter information here &gt;&gt;</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1.3. Pharmacokinetic properties of the API</th>
<th>Please enclose a copy of the literature references employed to document the PK properties (PK linearity or reasons for non-linearity).</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;&lt; Please enter information here &gt;&gt;</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1.4. Dosage form</th>
<th>Please confirm that:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• the dosage form is an immediate release product for systemic action</td>
<td></td>
</tr>
<tr>
<td>• the posology is limited to oral administration</td>
<td></td>
</tr>
<tr>
<td>• the administration without water is not included in the proposed posology</td>
<td></td>
</tr>
<tr>
<td>&lt;&lt; Please enter information here &gt;&gt;</td>
<td></td>
</tr>
</tbody>
</table>

| 1.0 COMMENTS FROM REVIEW OF SECTION 1 – EFDA official use only |                                                                                                           |
2. Solubility

Completion of this section is not necessary for the API(s) in which the solubility data established in literatures, official recognize monographs, SmPC of innovator products, public assessment reports and guidelines such as ICH guidelines, WHO TRS documents and other stringent regulatory authority guidelines).

2.1. Maximum therapeutic dose of the API
Please enclose a copy of the labelling of the comparator product to document the maximum single dose that can be administered in a single administration (e.g. two tablets together).

<< Please enter information here >>

2.2. Stability of the drug in the physiological pH range
Please discuss stability of the API in the pH range from 1.2 to 6.8 and in the gastrointestinal tract. Please discuss the ability of the analytical method to distinguish the API from its degradation products.

<< Please enter information here >>

2.3. Method of solubility determination
Please describe method and conditions (e.g. shake flask method at 37±1°C) Please also describe the solubility study protocol.

<< Please enter information here >>

2.4. Solubility study dates
Please indicate dates of study protocol, study conductance and study report

<< Please enter information here >>

2.5. Analytical method validation
Please summarise the results and indicate location in the documentation.

<< Please enter information here >>
2.6. Results
Please indicate location of the solubility study report.
Please fill in the following table for the necessary pH values. Add as many rows as necessary to create a solubility – pH profile

<table>
<thead>
<tr>
<th>Theoretical pH</th>
<th>Observed pH</th>
<th>Adjusted pH</th>
<th>Individual concentration at saturation (Cs) values</th>
<th>Cs (mean and CV(%))</th>
<th>Amount that can be dissolved in 250 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH 1.2</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
</tr>
<tr>
<td></td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
</tr>
<tr>
<td></td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
</tr>
<tr>
<td>Intermediate pHs</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
</tr>
<tr>
<td></td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
</tr>
<tr>
<td></td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
</tr>
<tr>
<td>pH 4.5</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
</tr>
<tr>
<td></td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
</tr>
<tr>
<td></td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
</tr>
<tr>
<td>Intermediate pHs</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
</tr>
<tr>
<td></td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
</tr>
<tr>
<td></td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
</tr>
<tr>
<td>pH 6.8</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
</tr>
<tr>
<td></td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
</tr>
<tr>
<td></td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
</tr>
<tr>
<td>Other intermediate pH values (e.g. pKa, pKa-1, pKa+1)</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
<td>Experiment 1</td>
</tr>
<tr>
<td></td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
<td>Experiment 2</td>
</tr>
<tr>
<td></td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
<td>Experiment 3</td>
</tr>
</tbody>
</table>

2.7. Plot the Solubility – pH profile
Please attach the plot of the pH-solubility profile based on the above data

<< Please enter information here >>

2.0 COMMENTS FROM REVIEW OF SECTION 2 – EFDA official USE ONLY
3. Absorption / Permeability

Completion of this section is not necessary for the API(s) in which the bioavailability (BA) and permeability data established in literatures, official recognize monographs, SmPC of innovator products, public assessment reports and guidelines such as ICH guidelines, WHO TRS documents and other stringent regulatory authorities guidance documents.

3.1. Human mass balance studies
Summarise results of all studies found in the literature.
Please enclose a copy of the references describing human mass balance studies of the API.

<< Please enter information here >>

3.2. Human absolute bioavailability studies
Summarise results of all studies found in the literature.
Please enclose a copy of the references describing human absolute bioavailability of the API.

<< Please enter information here >>

3.3. Supportive studies
Summarise results of all studies found in the literature regarding in vivo or in situ intestinal perfusion animal models or in vitro permeation across a monolayer of cultured epithelial cells (e.g. Caco-2) with a positive and negative control.
Please enclose a copy of the references.

<< Please enter information here >>

3.0 COMMENTS FROM REVIEW OF SECTION 3 – EFDA official use only
4. Test product

4.1 Tabulation of the composition of the formulation(s) proposed for marketing and those used for comparative dissolution studies

- Tabulate the composition of each product strength using the table below.
- For solid oral dosage forms the table should contain only the ingredients in tablet core or contents of a capsule. A copy of the table should be filled in for the film coating/hard capsule, if any.
- Biowaiver batches should be at least of pilot scale (10% of production scale or 100,000 capsules or tablets whichever is greater) and manufacturing method should be the same as for production scale.

Please note: If the formulation proposed for marketing and those used for comparative dissolution studies are not identical, copies of this table should be filled in for each formulation with clear identification in which study the respective formulation was used.

<table>
<thead>
<tr>
<th>Composition of the batches used for comparative dissolution studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batch number</td>
</tr>
<tr>
<td>Batch size (number of unit doses)</td>
</tr>
<tr>
<td>Date of manufacture</td>
</tr>
<tr>
<td>Comments, if any</td>
</tr>
<tr>
<td>Comparison of unit dose compositions and of clinical FPP batches</td>
</tr>
<tr>
<td>(duplicate this table for each strength, if compositions are different)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredients (Quality standard)</th>
<th>Unit dose (mg)</th>
<th>Unit dose (%)</th>
<th>Biobatch (kg)</th>
<th>Biobatch (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Equivalence of the compositions or justified differences

4.2 Potency (measured content) of test product as a percentage of label claim as per validated assay method

This information should be cross-referenced to the location of the Certificate of Analysis (CoA) in this biowaiver submission.

<< Please enter information here >>
4.0 COMMENTS FROM REVIEW OF SECTION 4 – EFDA official use only
5. Comparator product

5.1. Comparator product
A copy of product labelling (summary of product characteristics), as authorized in country of purchase, and translation into English, if appropriate.
A copy of the comparator product carton outer box. The name of the product, name and address of the manufacturer, batch number, and expiry date should be clearly visible on the labelling.
This information should be cross-referenced to the location of the Certificate of Analysis (CoA) in this biowaiver submission.

<< Please enter information here >>

5.2. Name and manufacturer of the comparator product and official address

<< Please enter information here >>

5.3. Qualitative (and quantitative, if available) information on the composition of the comparator product
Please tabulate the composition of the comparator product based on available information and state the source of this information.

<table>
<thead>
<tr>
<th>Composition of the comparator product used in dissolution studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batch number</td>
</tr>
<tr>
<td>Expiry date</td>
</tr>
<tr>
<td>Comments, if any</td>
</tr>
<tr>
<td>Ingredients</td>
</tr>
<tr>
<td>Ingredients</td>
</tr>
<tr>
<td>Ingredients</td>
</tr>
<tr>
<td>Ingredients</td>
</tr>
</tbody>
</table>

5.4. Potency (measured content) of the comparator product as a percentage of label claim, as measured by the same laboratory under the same conditions as the test product.
This information should be cross-referenced to the location of the Certificate of Analysis (CoA) in this biowaiver submission.

<< Please enter information here >>

| 5.0 | COMMENTS FROM REVIEW OF SECTION 5 – EFDA official use only |
6. Comparison of test and comparator formulations

6.1. Identify any excipients present in either product that are known to impact *in vivo* absorption processes
A literature-based summary of the mechanism by which these effects are known to occur should be included and relevant full discussion enclosed, if applicable.

<< Please enter information here >>

6.2. Identify all qualitative (and quantitative, if available) differences between the compositions of the test and comparator products
The data obtained and methods used for the determination of the quantitative composition of the comparator product as required by the guidance documents should be summarized here for assessment.

<< Please enter information here >>

6.3. Provide a detailed comment on the impact of any differences between the compositions of the test and comparator products with respect to drug release and *in vivo* absorption

<< Please enter information here >>

6.0 COMMENTS FROM REVIEW OF SECTION 6 – EFDA official use only
# 7. Comparative in vitro dissolution

## 7.1. Comparative in vitro dissolution

Information regarding the comparative dissolution studies should be included below to provide adequate evidence supporting the biowaiver request. Comparative dissolution data will be reviewed during the assessment of the Quality part of the dossier. Please state the location of:

- the dissolution study protocol(s) in this biowaiver application
- the dissolution study report(s) in this biowaiver application
- the analytical method validation report in this biowaiver application

<< Please enter information here >>

## 7.2. Dissolution study dates

Please indicate dates of study protocol, study conductance and study report

<< Please enter information here >>

## 7.3. Summary of the dissolution conditions and method described in the study report(s)

Summary provided below should include the composition, temperature, volume, and method of de-aeration of the dissolution media, the type of apparatus employed, the agitation speed(s) employed, the number of units employed, the method of sample collection including sampling times, sample handling, filtration and storage. Deviations from the sampling protocol should also be reported.

### 7.3.1. Dissolution media: Composition, temperature, volume, and method of de-aeration

<< Please enter information here >>

### 7.3.2. Type of apparatus and agitation speed(s) employed

<< Please enter information here >>
7.3.3. Number of units employed

<< Please enter information here >>

7.3.4. Sample collection: method of collection, sampling times, sample handling, filtration and storage

<< Please enter information here >>

7.3.5. Deviations from sampling protocol

<< Please enter information here >>

7.4. Summarize the results of the dissolution study(s)
Please provide a tabulated summary of individual and mean results with %CV, graphic summary, and any calculations used to determine the similarity of profiles for each set of experimental conditions.

<< Please enter information here >>

7.5. Summarize conclusions taken from dissolution study(s)
Please provide a summary statement of the studies performed.

<< Please enter information here >>

7.6. Dissolution specifications
Please provide proposed dissolution specifications and discuss them in relation to the results obtained in the BCS biowaiver.

<< Please enter information here >>
Annex II: Biowaiver Application Form: Dose-proportionality formulations

This application form is designed to facilitate information exchange between the Applicant and the EFDA if a biowaiver is requested for additional strength(s) of the submitted product(s).

A request for a waiver from the requirement for conducting bioequivalence studies on additional strengths of the product submitted for assessment to the EFDA can be made based on the proportionality of the formulations of the series of strengths. If additional strengths are proposed and a biowaiver for these strengths is sought, the following information should be provided:

Final assessment of the proportionality of the proposed formulations and the acceptability of the comparative dissolution data will be made during the evaluation of Quality part of the dossier.

<table>
<thead>
<tr>
<th>Administrative data</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Name of the product (Brand name &amp; INN of active ingredient(s))</strong></td>
</tr>
<tr>
<td>&lt; Please enter information here &gt;</td>
</tr>
<tr>
<td><strong>2. Dosage form and strengths</strong></td>
</tr>
<tr>
<td>&lt; Please enter information here &gt;</td>
</tr>
<tr>
<td><strong>3. Product WHO Reference numbers</strong></td>
</tr>
<tr>
<td>(if available for any strengths of the product line, including the reference strength)</td>
</tr>
<tr>
<td>&lt; Please enter information here &gt;</td>
</tr>
<tr>
<td><strong>4. Name of applicant and official address</strong></td>
</tr>
<tr>
<td>&lt; Please enter information here &gt;</td>
</tr>
</tbody>
</table>
5. Name of manufacturer of finished product and official address

   < Please enter information here >

6. Name and address of the laboratory or Contract Research Organisation(s) where the biowaiver dissolution studies were conducted (if applicable)

   < Please enter information here >

---

I, the undersigned, certify, that the information provided in this application and the attached documents is correct and true

Signed on behalf of

<company>

_________________ (Date)

_____________________________________ (Name and title)
1. Test product

1.1 Tabulation of the composition of formulation proposed for marketing

- For solid oral dosage forms the table should contain only the ingredients in tablet core or contents of a capsule. A copy of the table should be filled in for the film coating or hard capsule, if any.
- Biowaiver batches should be at least of pilot scale (10% of production scale or 100,000 capsules or tablets whichever is greater) and manufacturing method should be the same as for production scale.

<table>
<thead>
<tr>
<th>Composition of the batch used for comparative dissolution studies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Batch number for biowaiver batch</strong></td>
</tr>
<tr>
<td><strong>Batch size (number of unit doses)</strong></td>
</tr>
<tr>
<td><strong>Date of manufacture</strong></td>
</tr>
<tr>
<td><strong>Expiry date</strong></td>
</tr>
<tr>
<td><strong>Comments, if any</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Unit dose compositions and FPP batch composition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ingredients (Quality standard)</strong></td>
</tr>
<tr>
<td><strong>Unit dose (mg)</strong></td>
</tr>
<tr>
<td><strong>Unit dose (%)</strong></td>
</tr>
<tr>
<td><strong>Biowaiver batch (kg)</strong></td>
</tr>
<tr>
<td><strong>Biowaiver batch (%)</strong></td>
</tr>
</tbody>
</table>

1.2 Potency (measured content) of test product as a percentage of label claim as per validated assay method

This information should be cross-referenced to the location of the Certificate of Analysis (CoA) in this biowaiver submission.

<<< Please enter information here >>>

1.3 Pharmacokinetics

- State whether the drug displays linear or non-linear pharmacokinetics
2. Reference strength

2.1. Reference strength
In this context, the reference strength is the strength of the FPP that was compared to the Comparator product in an in vivo bioequivalence study.

2.2. Tabulation of batch information for the reference strength
The biobatch of the reference strength (batch employed in the in vivo bioequivalence study) should be employed in the comparative dissolution studies.

<table>
<thead>
<tr>
<th>Batch information for batch used for comparative dissolution studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batch number</td>
</tr>
<tr>
<td>Batch size (number of unit doses)</td>
</tr>
<tr>
<td>Date of manufacture</td>
</tr>
<tr>
<td>Expiry date</td>
</tr>
<tr>
<td>Comments, if any</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Unit dose compositions and FPP batch composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ingredients (Quality standard)</td>
</tr>
<tr>
<td>Unit dose (mg)</td>
</tr>
<tr>
<td>Unit dose (%)</td>
</tr>
<tr>
<td>Batch (kg)</td>
</tr>
<tr>
<td>Batch (%)</td>
</tr>
</tbody>
</table>
2.3. Batch confirmation
If the batch of reference strength employed in the comparative dissolution studies was not the biobatch of the reference strength (batch employed in the in vivo bioequivalence study), the following information should be provided:
- Batch number of biobatch
- Justification for use of a batch other than the biobatch
- Comparative dissolution data for batch employed vs. (historical data for) biobatch
- As an Appendix, executed batch manufacturing records (BMR) for batch employed in dissolution studies

2.4 Potency (measured content) of reference product as a percentage of label claim as per validated assay method
This information should be cross-referenced to the location of the Certificate of Analysis (CoA) in this biowaiver submission.

2.5 Comments from review of Section 2.1 – 2.4 – EFDA official use only

3. Comparison of Test and Reference strengths

3.1. Tabulation of batch information for the test and reference strengths
For solid oral dosage forms the table should contain only the ingredients in tablet core or contents of a capsule. A copy of the table should be filled in for the film coating or hard capsule, if any.
### Component and Quality Standard

<table>
<thead>
<tr>
<th>Component and Quality Standard</th>
<th>Function</th>
<th>Strength (label claim)</th>
<th>Quantity per unit</th>
<th>%*</th>
<th>Quantity per unit</th>
<th>%*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>XX mg</td>
<td></td>
<td></td>
<td>XX mg</td>
<td></td>
</tr>
</tbody>
</table>

*each ingredient expressed as a percentage of the total core

---

### 3.2. Confirmation of Proportionality

Applicant should confirm that the test and reference strength formulations are directly proportional. Any deviations from direct proportionality should be identified and justified in detail.

<< Please enter information here >>

### 3.3 Comments from review of Section 3.1 – 3.2 – EFDA official use only

---

### 4. Comparative *in vitro* dissolution:

**Studies comparing different strengths of the test product**

- Comparative dissolution data will be reviewed during the assessment of the Quality part of the dossier.
- As per Annex IV- Recommendation for conducting and assessing a dissolution profile of this guidance document, comparative dissolution studies should be conducted in pH 1.2, 4.5, and 6.8 media. If the proposed dissolution medium for release of the products differs from these media, comparative dissolution data in the proposed release medium should also be provided.
- Summary information regarding the comparative dissolution studies should be included below to provide a complete summary of the data supporting the biowaiver request.

---

### 4.1. Please state the location of:
- the dissolution study protocol(s) in the dossier
- the dissolution study report(s) in the dossier
- the analytical method validation report in the dossier

4.2. Summary of the dissolution conditions and method described in the study report(s)
Summary provided below should include the composition, temperature, volume, and method of de-aeration of the dissolution media, the type of apparatus employed, the agitation speed(s) employed, the number of units employed, the method of sample collection including sampling times, sample handling, and sample storage. Deviations from the sampling protocol should also be reported.

4.2.1. Dissolution media: Composition, temperature, volume, and method of de-aeration

4.2.2. Type of apparatus and agitation speed(s) employed

4.2.3. Number of units employed

4.2.4. Sample collection: method of collection, sampling times, method of filtration, sample handling and storage

4.2.5. Deviations from sampling protocol
### 4.3. Summarize the results of the dissolution study(s)

Please provide a tabulated summary of individual and mean results with %CV, graphic summary, and any calculations used to determine the similarity of profiles for each set of experimental conditions.

<< Please enter information here >>

### 4.4. Summarize conclusions taken from dissolution study(s)

Please provide a summary statement of the studies performed.

<< Please enter information here >>

### 4.5. Comments from review of Section 4.1 – 4.4 – EFDA official use only

---

### 5. Comparative in vitro dissolution:

Studies comparing each strength of the test product to equivalent strength of comparator product; only to be submitted in case in vitro dissolution data between different strengths of Test product (see Section 4) are not similar

- This section is applicable in cases where, due to low solubility of the API, similar comparative dissolution between differing strengths is difficult to achieve. The WHO comparator product as identified on the programme’s website should be employed.
- Comparative dissolution data will be reviewed during the assessment of the Quality part of the dossier.
- Annex IV- Recommendation for conducting and assessing a dissolution profile of this guidance, comparative dissolution studies should be conducted in pH 1.2, 4.5, and 6.8 media. If the proposed dissolution medium for release of the products differs from these media, comparative dissolution data in the proposed release medium should also be provided.
- Summary information regarding the comparative dissolution studies should be included below to provide a complete summary of the data supporting the biowaiver request.

### 5.1. Potency (measured content) of the comparator product as a percentage of label claim, as measured by the same laboratory under the same conditions as the test product.

This information should be cross-referenced to the location of the Certificate of Analysis (CoA) in this biowaiver submission.
5.2. Please state the location of:
- the dissolution study protocol(s) in the dossier
- the dissolution study report(s) in the dossier
- the analytical method validation report in the dossier
5.3.5. Deviations from sampling protocol

<< Please enter information here >>

5.4. Summarize the results of the dissolution study(s)
Please provide a tabulated summary of individual and mean results with %CV, graphic summary, and any calculations used to determine the similarity of profiles for each set of experimental conditions.

<< Please enter information here >>

5.5. Summarize conclusions taken from dissolution study(s)
Please provide a summary statement of the studies performed.

<< Please enter information here >>

5.7. Comments from review of Section 5.1 – 5.5 – EFDA official use only

CONCLUSIONS AND RECOMMENDATIONS – EFDA official use only
Annex IV: Recommendations for conducting and assessing comparative dissolution profiles

The dissolution measurements of the two finished pharmaceutical product (FPPs (e.g. test and comparator or two different strengths) should be made under the same test conditions. A minimum of three time-points (zero excluded) should be included, the time-points for both reference (comparator) and test product being the same. The sampling intervals should be short for a scientifically sound comparison of the profiles (e.g. 5, 10, 15, 20, 30, 45 and 60 minutes for an immediate-release dosage form). The 15-minute time-point is critical to determine whether a product is very rapidly dissolving and to determine whether $f_2$ must be calculated. For extended-release FPPs the time-points should be set to cover the entire duration of expected release, e.g. in addition to earlier time-points: samples at 1, 2, 3, 5 and 8 hours should be collected for a 12-hour release and additional test intervals would be necessary for longer duration of release.

Studies should be performed in at least three media covering the physiological range, including pH 1.2 hydrochloric acid, pH 4.5 buffer and pH 6.8 buffer. Ph.Int. buffers are recommended; other pharmacopoeial buffers with the same pH and buffer capacity are also accepted. Water may be considered as an additional medium, especially when the API is unstable in the buffered media to the extent that the data are unusable.

If both the test and reference (comparator) products show more than 85% dissolution in 15 minutes the profiles are considered similar (no calculations required). Otherwise:

- similarity of the resulting comparative dissolution profiles should be calculated using the following equation that defines a similarity factor ($f_2$)

\[
f_2 = 50 \log \left\{ \left[ 1+1/n \sum_{i=1}^{n} \left( R_i - T_i \right) \right]^{2} \times 100 \right\}
\]

where $R_t$ and $T_t$ are the mean per cent API dissolved in reference (comparator) and test product, respectively, at each time-point. An $f_2$ value between 50 and 100 suggests that the two dissolution profiles are similar;
• a maximum of one time-point should be considered after 85% dissolution of the reference (comparator) product has been reached;

• in the case where 85% dissolution cannot be reached owing to poor solubility of the API or the release mechanism of the dosage form, the dissolution should be conducted until an asymptote (plateau) has been reached;

• at least 12 units should be used for determination of each profile. Mean dissolution values can be used to estimate the similarity factor, f₂. To use mean data the percentage coefficient of variation at time-points up to 10 minutes should be not more than 20% and at other time-points should be not more than 10%;

• when delayed-release products (e.g. enteric coated) are being compared, the recommended conditions are acid medium (pH 1.2) for 2 hours and buffer pH 6.8 medium;

• when comparing extended-release beaded capsules, where different strengths have been achieved solely by means of adjusting the number of beads containing the API, one condition (normally the release condition) will suffice;

• surfactants should be avoided in comparative dissolution testing.

A statement that the API is not soluble in any of the media is not sufficient, and profiles in the absence of surfactant should be provided. The rationale for the choice and concentration of surfactant should be provided. The concentration of the surfactant should be such that the discriminatory power of the test will not be compromised.
REFERENCE


Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, Guidance for Industry U.S. FDA, December 2017


